Cytotoxic T lymphocyte

• US 20060073126A1
• Filed: 07/01/2005
• Published: 04/06/2006
• Est. Priority Date: 10/01/2004
• Status: Abandoned Application

• Current Assignee: MIE University, Takara Bio Incorporated (Ningbo Junsheng Investment Group Co., Ltd.)
• Original Assignee: MIE University, Takara Bio Incorporated (Ningbo Junsheng Investment Group Co., Ltd.)
• Inventors: Okumura, Satoshi, Miyahara, Yoshihiro, Hiasa, Atsunori, Naota, Hiroaki, Shiku, Hiroshi
• Application Number:
  US11/171,365
• Publication Number:
  US 20060073126A1
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: A61K 2039/5154 Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
• CPC Class Codes: A61K 2039/5156 expressing foreign proteins
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 5/0636 T lymphocytes

Abstract

The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte.

Claims

1. An RNA-introduced T lymphocyte into which an RNA encoding an antigen of interest is introduced, which has an activity to induce a T lymphocyte which recognizes the antigen.

2. The RNA-introduced T lymphocyte according to claim 1, which is a CD4-positive cell activated with phytohemagglutinin.

9. An immune inducer containing the RNA-introduced T lymphocyte as defined in claim 1 or 2.

3. A method for inducing a T lymphocyte, comprising using, as an antigen-presenting cell, an RNA-introduced T lymphocyte into which an RNA encoding an antigen of interest is introduced, to induce a T lymphocyte which recognizes the antigen.

4. The method according to claim 3, wherein the RNA-introduced T lymphocyte is a CD4-positive cell activated with phytohemagglutinin.

5. The method according to claim 3, wherein the T lymphocyte which recognizes the antigen is a cytotoxic T lymphocyte positive to CD8.

6. The method according to any one of claims 3 to 5, wherein the antigen is a tumor-associated antigen or an antigen of an infectious microorganism.

7. The method according to claim 6, wherein the RNA is an RNA prepared from a cancer tissue.

8. The method according to claim 6, wherein the antigen is EBNA3A and/or CMVpp65.

10. A therapeutic agent for cancer or infectious disease, containing the T lymphocyte obtained by the method of any one of claims 3 to 8 as an active ingredient.

11. A cytotoxic T lymphocyte which recognizes a cell presenting on the surface thereof a complex of a human major histo-compatibility antigen (HLA)-A24-restricted antigen peptide represented by SEQ ID NO:

1 or 2 and an HLA-A24 molecule or a complex of a functional derivative of the HLA-A24-restricted antigen peptide and an HLA-A24 molecule, and which is CD8-positive.

12. A therapeutic agent for cancer, containing the cytotoxic T lymphocyte of claim 11.

13. An inducer of the cytotoxic T lymphocyte of claim 11, containing at least one peptide selected from the group consisting of a human major histo-compatibility antigen (HLA)-A24-restricted antigen peptide represented by SEQ ID NO:

1 or 2 and a functional derivative thereof as an active ingredient.

15. A tetramer for detecting a T cell receptor possessed by the cytotoxic T lymphocyte of claim 11, comprising a human major histo-compatibility antigen (HLA)-A24-restricted antigen peptide represented by SEQ ID NO:

1 or 2 or a functional derivative thereof.

14. A therapeutic agent for cancer, containing a human major histo-compatibility antigen (HLA)-A24-restricted antigen peptide represented by SEQ ID NO:

1 or 2 and a functional derivative thereof as an active ingredient.